Work

Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results

Year: 2022

Type: preprint

Study design: Clinical Trial

Source: SSRN Electronic Journal

DOI: 10.2139/ssrn.4195069

Authors: Anwaar Saeed, Robin Park, Junqiang Dai, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Stephen Williamson, Azhar Saeed, Jacob Ripp, Zachary Collins, Kelly Mulvaney, Molly Shugrue, Jeanette Firth-Braun, Shrikant Anant, Andrew K. Godwin, Rashna Madan, Milind Phadnis, Weijing Sun

Institutions: University of Minnesota, University of Kansas, The University of Kansas Cancer Center, Moffitt Cancer Center, The University of Kansas Health System

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4295858048

Cites: 170

Cited by: 1

Related to: 10